| Effectiveness of Upper Extremity Rehabilitation in pwFSHD (Patient With Facioscapulohumeral Dystrophia) (NCT05178706) | Istanbul University - Cerrahpasa | 2022-02-22 |
| Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) (NCT03943290) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2019-05-10 |
| Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (NCT03458832) | University of Kansas Medical Center | 2018-03-05 |
| Study of Testosterone and rHGH in FSHD (NCT03123913) | University of Rochester | 2017-12-18 |
| Arm Cycling in Facioscapulohumeral Dystrophy (FSHD) Patients (NCT04267354) | Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust | 2016-12-14 |
| Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (NCT02927080) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2016-11-01 |
| Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) (NCT02836418) | aTyr Pharma, Inc. | 2016-07-13 |
| Rasch-analysis of Clinical Severity in FSHD (NCT02766985) | University of Kansas Medical Center | 2016-03-01 |
| Facioscapulohumeral Dystrophy in Children (NCT02625662) | University Medical Center Nijmegen | 2015-11-01 |
| Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension (NCT02531217) | aTyr Pharma, Inc. | 2015-08-13 |
| Biomarker Development for Muscular Dystrophies (NCT05019625) | Massachusetts General Hospital | 2015-02-20 |
| Bone Health in Facioscapulohumeral Muscular Dystrophy (NCT02413190) | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 2014-07-01 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry (NCT04001582) | Newcastle University | 2013-05-01 |
| A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD (NCT01437345) | Cooperative International Neuromuscular Research Group | 2012-07-01 |
| Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy (NCT01671865) | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 2012-03-01 |
| Electrostimulation of Shoulder Girdle and Quadriceps Muscles in Facioscapulohumeral Muscular Dystrophy Patients (NCT00821548) | Centre Hospitalier Universitaire de Nice | 2008-01-01 |
| Study Evaluating MYO-029 in Adult Muscular Dystrophy (NCT00104078) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-02-01 |